1. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
- Author
-
Fortin BM, Pfeiffer SM, Insua-Rodríguez J, Alshetaiwi H, Moshensky A, Song WA, Mahieu AL, Chun SK, Lewis AN, Hsu A, Adam I, Eng OS, Pannunzio NR, Seldin MM, Marazzi I, Marangoni F, Lawson DA, Kessenbrock K, and Masri S
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Circadian Rhythm immunology, CD8-Positive T-Lymphocytes immunology, Colorectal Neoplasms immunology, Colorectal Neoplasms therapy, Colorectal Neoplasms drug therapy, Tumor Microenvironment immunology, Immune Tolerance, Humans, Female, Cell Line, Tumor, Single-Cell Analysis, Immunosuppression Therapy, Cytokines metabolism, Male, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology, Myeloid-Derived Suppressor Cells immunology, Myeloid-Derived Suppressor Cells metabolism, Circadian Clocks immunology, B7-H1 Antigen metabolism, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen immunology
- Abstract
The circadian clock is a critical regulator of immunity, and this circadian control of immune modulation has an essential function in host defense and tumor immunosurveillance. Here we use a single-cell RNA sequencing approach and a genetic model of colorectal cancer to identify clock-dependent changes to the immune landscape that control the abundance of immunosuppressive cells and consequent suppression of cytotoxic CD8
+ T cells. Of these immunosuppressive cell types, PD-L1-expressing myeloid-derived suppressor cells (MDSCs) peak in abundance in a rhythmic manner. Disruption of the epithelial cell clock regulates the secretion of cytokines that promote heightened inflammation, recruitment of neutrophils and the subsequent development of MDSCs. We also show that time-of-day anti-PD-L1 delivery is most effective when synchronized with the abundance of immunosuppressive MDSCs. Collectively, these data indicate that circadian gating of tumor immunosuppression informs the timing and efficacy of immune checkpoint inhibitors., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)- Published
- 2024
- Full Text
- View/download PDF